Scientific Reference
Survodutide (BI 456906)
Evidence profile: Human Phase 3 evidence
Survodutide (BI 456906) is an investigational dual glucagon receptor and GLP-1 receptor agonist. It is a 29-amino acid peptide with C18 fatty acid acylation, a modification that extends its duration of action and supports once-weekly administration in study protocols. Its dual mechanism engages both receptors rather than one, and is the subject of ongoing published research. Survodutide is not an approved medicine. Supplied strictly as a research compound for laboratory use.
Published Research
SYNCHRONIZE-1
Survodutide Once Weekly for the Treatment of Adults with Obesity
le Roux CW et al. · The New England journal of medicine · 2026 · Clinical
PMID 42253238 — View on PubMedSYNCHRONIZE-MASLD
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial
Kaplan LM et al. · Nature medicine · 2026 · Clinical
PMID 42252333 — View on PubMedA Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
Sanyal AJ et al. · The New England journal of medicine · 2024 · Clinical
PMID 38847460 — View on PubMedGlucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
le Roux CW et al. · The lancet. Diabetes & endocrinology · 2024 · Clinical
PMID 38330987 — View on PubMedBaseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes
Wharton S et al. · Diabetes, obesity & metabolism · 2026 · Clinical
PMID 41216778 — View on PubMedDose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
Blüher M et al. · Diabetologia · 2024 · Clinical
PMID 38095657 — View on PubMed